# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-23-000039
Filing Date
2023-08-03
Accepted
2023-08-03 16:35:09
Documents
68
Period of Report
2023-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sava-20230630x10q.htm iXBRL | 10-Q | 2177318
2 | EX-10.2 | sava-20230630xex10_2.htm | EX-10.2 | 156507
3 | EX-10.3 | sava-20230630xex10_3.htm | EX-10.3 | 51446
4 | EX-31.1 | sava-20230630xex31_1.htm | EX-31.1 | 25409
5 | EX-31.2 | sava-20230630xex31_2.htm | EX-31.2 | 25247
6 | EX-32.1 | sava-20230630xex32_1.htm | EX-32.1 | 20224
7 | GRAPHIC | sava-20230630x10qg001.jpg | GRAPHIC | 62088
8 | GRAPHIC | sava-20230630x10qg002.jpg | GRAPHIC | 77567
9 | GRAPHIC | sava-20230630x10qg003.jpg | GRAPHIC | 46334
10 | GRAPHIC | sava-20230630x10qg004.jpg | GRAPHIC | 42887
11 | GRAPHIC | sava-20230630x10qg005.jpg | GRAPHIC | 45499
12 | GRAPHIC | sava-20230630x10qg006.jpg | GRAPHIC | 93477
13 | GRAPHIC | sava-20230630xex10_3g001.jpg | GRAPHIC | 35453
| Complete submission text file | 0001069530-23-000039.txt |  | 8082044

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
14 | EX-101.SCH | sava-20230630.xsd | EX-101.SCH | 32038
15 | EX-101.CAL | sava-20230630_cal.xml | EX-101.CAL | 35336
16 | EX-101.DEF | sava-20230630_def.xml | EX-101.DEF | 104791
17 | EX-101.LAB | sava-20230630_lab.xml | EX-101.LAB | 259117
18 | EX-101.PRE | sava-20230630_pre.xml | EX-101.PRE | 228418
62 | EXTRACTED XBRL INSTANCE DOCUMENT | sava-20230630x10q_htm.xml | XML | 1306624

Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 231140691
SIC: 2834 Pharmaceutical Preparations